NCT05508841 Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation
| NCT ID | NCT05508841 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baycrest |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2022-09-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.
Eligibility Criteria
Inclusion Criteria: * Mild to Moderate AD * Score between 18 and 25 on the MoCA * Able to do the N-Back task during the initial screening Exclusion Criteria: * No history of stroke or TBI * No shunts or metal in the body * No history of significant heart disease, alcoholism and drug use
Contact & Investigator
Carlos Roncero, PhD
✉ troncero@research.baycrest.orgFrequently Asked Questions
Who can join the NCT05508841 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05508841 currently recruiting?
Yes, NCT05508841 is actively recruiting participants. Contact the research team at troncero@research.baycrest.org for enrollment information.
Where is the NCT05508841 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05508841 clinical trial?
NCT05508841 is sponsored by Baycrest. The trial plans to enroll 42 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.